title: Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
abstract: Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most important role. It has been demonstrated that the Fc-attached sugar moiety is essential for IgG effector functionality, dictates its affinity to individual FcγRs and determines binding to different receptor classes: activating or inhibitory. In this study, we systematically analyze effector functions of monoclonal IgG1 and its eight enzymatically engineered glycosylation variants. The analysis of interaction of glycovariants with FcRs was performed for single, as well as for antigen-bound antibodies and IgGs in a form of immune complex. In addition to functional properties we addressed impact of glycosylation on the structural properties of the tested glycovariants. We demonstrate a clear impact of glycosylation pattern on antibody stability and interaction with different FcγRs. Consistent with previous reports, deglycosylated antibodies failed to bind all Fcγ-receptors, with the exception of high affinity FcγRI. The FcγRII and FcγRIIIa binding activity of IgG1 was observed to depend on the galactosylation level, and hypergalactosylated antibodies demonstrated increased receptor interaction. Sialylation did not decrease the FcγR binding of the tested IgGs; in contrast, sialylation of antibodies improved binding to FcγRIIa and IIb. We demonstrate that glycosylation influences to some extent IgG1 interaction with FcRn. However, independent of glycosylation pattern the interaction of IgG1 with a soluble monomeric target surprisingly resulted in an impaired receptor binding. Here, we demonstrate, that immune complexes (IC), induced by multimeric ligand, compensated for the decreased affinity of target bound antibody towards FcRs, showing the importance of the IC-formation for the FcR- mediated effector functions.
authors.affiliation: Biochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.|Center for Integrated Protein Science Munich, Department Chemie, Technische Universität München, 85748, Garching, Germany.
authors.forename: Tetyana
authors.initials: T
authors.lastname: Dashivets
authors.affiliation: Pharma Biotech Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany.
authors.forename: Marco
authors.initials: M
authors.lastname: Thomann
authors.affiliation: Biochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Rueger
authors.affiliation: Biochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Knaupp
authors.affiliation: Center for Integrated Protein Science Munich, Department Chemie, Technische Universität München, 85748, Garching, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Buchner
authors.affiliation: Biochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
authors.forename: Tilman
authors.initials: T
authors.lastname: Schlothauer
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D000915:Antibody Affinity; D000936:Antigen-Antibody Complex / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D002240:Carbohydrate Sequence; D002460:Cell Line; D002846:Chromatography, Affinity; D005690:Galactose / Q000276:immunology / Q000378:metabolism; D015870:Gene Expression; D006031:Glycosylation; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D008969:Molecular Sequence Data; D011485:Protein Binding; D015202:Protein Engineering; D055550:Protein Stability; D017452:Receptors, IgG / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D012794:Sialic Acids / Q000276:immunology / Q000378:metabolism; D020349:Surface Plasmon Resonance
chemical_list: D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; C489017:FCGR1A protein, human; C080568:Fc gamma receptor IIA; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D017452:Receptors, IgG; D011994:Recombinant Proteins; D012794:Sialic Acids; D005690:Galactose